Atrium: Cardiology Products




					Atrium’s vast expertise in developing technologies for the treatment of cardiovascular disease has brought breakthrough technologies to those unmet clinical needs in interventional cardiology, including coronary stents with and without drug eluting coatings, and advanced balloon PTCA technology. Atrium has delivered over 25,000 successful interventions with Flyer RX. Along with a high quality next generation rapid exchange PTCA balloon catheter called Hyperlite LX, Flyer and HyperLite provide cardiologists with an outstanding choice as the first step in reperfusion. Flyer remains one of the lowest crossing profile stents commercially available. Flyer offers the unique combination of unmatched trackability, amazing flexibility, and precision deployment. The Advanta™ V12 covered stent is the first balloon expandable PTFE covered stent to be completely encapsulated, eliminating direct contact of the stent with the vessel wall. By completely encapsulating the stent with a proven biocompatible and micro-porous PTFE film the V12's design helps reduce tissue prolapse. Atrium's extraordinary low profile covered stent is an extremely easy to deploy covered stent designed to fit through most 6Fr and 7Fr introducers. In a number of countries around the globe, Atrium has now become recognized as an innovator in this rapidly evolving Interventional Cardiology market. Atrium’s V12, Flyer and HyperLite LX coronary reperfusion products are CE approved and currently available in a wide variety of sizes around the world.

Using the latest in engineering CAD design, FEA analysis and utilizing next generation coating technologies, together with evolving therapeutics options, Atrium is bringing a future of revolutionary products to the interventional cardiology and peripheral vascular markets. Atrium began this journey by first designing a world-class stent platform with narrow struts and a unique cell geometry. Utilizing proprietary crimping technology, Flyer offers tremendous flexibility with a super low crossing profile to reach virtually every coronary target lesion.

These next-generation interventional technologies provide Atrium with a broad spectrum of innovative coronary products to achieve “total lesion” therapeutic care for even the most challenging patients. As a result of Atrium’s scientific advances in both biological and device technologies, we will continue to revolutionize the interventional cardiology market.

Please contact Atrium’s Interventional Cardiology Systems team to learn more about our innovative coronary products and exciting therapeutic solutions currently in development.